Peter Aaby

Please go to for more information. In short CCIT comprise clinical and experimental expertise in tumor immunology. The Centre has approx. 25 employees; scientists, clinicians, PhD students, as well as technicians. The Centre has extensive experience in initiating clinical trials in cancer, and more than 100 cancer patients have been vaccinated with dendritic cell based therapeutic vaccinations and new facilities for GCP production of cellular products for clinical use was recently opened, enabling trials using adoptive cell transfer of tumor specific T cells.
Type Angel Investor

Investment info

Invests in
Product or prototype
Go to market
Growth and expansion
Investment range
€ < 25K
€ 25 - 50K
€ 50 - 100K
€ 100 - 500K
Primary markets
Consumer, Companies, Marketplace, Government
Investing in countries

Focus areas

Healthcare & Life Science
Healthcare & Life Science
Science & Engineering
Science & Engineering

Key people

Board Member & Engineer

Peter Aaby

This profile is currently managed by The Hub, .